Modulating the alternative complement pathway
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsJOSHUA M. THURMAN, V. MICHAEL HOLERS
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.
Claims22
-20. (canceled)
A method of modulating alternative complement activity in an individual, the method comprising administering to an individual in need thereof a composition comprising a fusion protein, the fusion protein comprising an anti-annexin A2 antibody or an antigen-binding fragment thereof fused to a complement inhibitor selected from the group consisting of decay-accelerating factor (DAF), factor H, membrane cofactor protein (MCP), CD59, complement receptor 1 (CR1), and mouse complement receptor 1-related gene/protein y (Crry protein), or a biologically-active fragment thereof.
A composition for modulating alternative complement activity, the composition comprising a fusion protein comprising an anti-annexin A2 antibody or an antigen-binding fragment thereof fused to a complement inhibitor selected from the group consisting of decay-accelerating factor (DAF), factor H, membrane cofactor protein (MCP), CD59, complement receptor 1 (CR1), and mouse complement receptor 1-related gene/protein y (Crry protein), or a biologically-active fragment thereof;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.